Literature DB >> 18475594

Differential Proliferative Characteristics of Alveolar Fibroblasts in Interstitial Lung Diseases: Regulative Role of IL-1 and PGE(2).

E Fireman1, S Ben Efraim, J Greif, H Peretz, S Kivity, M Topilsky, Y Rodrig, A Yellin, R N Apte.   

Abstract

Fibroblasts (Fb) from patients with sarcoidosis (SA) and hypersensitivity pneumonitis (HP) exhibited a lower proliferative capacity compared with Fb obtained from control (CO) and diffuse interstitial fibrosis patients (DIF). Proliferation of Fb from SA or lip patients was suppressed by autologous LPS-stimulated alveolar macrophages (AM) supernatants but not by those from CO patients. Similarly, alveolar macrophages (AM) derived supernatant, obtained from CO, did not suppress the proliferation of SA and HP Fb. AM from SA and HP patients secreted higher amounts of IL-1alpha and beta compared with controls and compared with Fb from SA and HP patients. Steady levels of IL-1alpha and betamRNA were expressed in unstimulated and stimulated cultures. Fb from SA and HP patients could be stimulated by LPS to secrete significantly higher levels of PGE(2) than those detected in supernatants from LPS stimulated Fb of DIF patients. Only the proliferation of Fb from SA and HP patients was sensitive to amounts of IL-1 equivalent to those detected in the lung of these diseases. As SA and HP are two diseases where irreversible deterioration occurs in only 20% of the patients, we hypothesize that mediators in the lung may modulate Fb proliferation. IL-1 of AM origin and PGE(2) of Fb origin secreted at high levels, may be candidates for this suppression because it was abrogated by anti IL-1beta and indomethacin.

Entities:  

Year:  1994        PMID: 18475594      PMCID: PMC2365581          DOI: 10.1155/S0962935194000633

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  22 in total

1.  Cathepsin-G and leukocyte elastase inactivate human tumor necrosis factor and lymphotoxin.

Authors:  P Scuderi; P A Nez; M L Duerr; B J Wong; C M Valdez
Journal:  Cell Immunol       Date:  1991-07       Impact factor: 4.868

2.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.

Authors:  C H Hannum; C J Wilcox; W P Arend; F G Joslin; D J Dripps; P L Heimdal; L G Armes; A Sommer; S P Eisenberg; R C Thompson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

3.  Interleukin-1 beta stimulates fibroblast elastase activity.

Authors:  F Croute; E Delaporte; J Y Bonnefoy; C Fertin; J Thivolet; J F Nicolas
Journal:  Br J Dermatol       Date:  1991-06       Impact factor: 9.302

4.  Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells.

Authors:  C Zoja; J M Wang; S Bettoni; M Sironi; D Renzi; F Chiaffarino; H E Abboud; J Van Damme; A Mantovani; G Remuzzi
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

5.  Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein.

Authors:  D B Carter; M R Deibel; C J Dunn; C S Tomich; A L Laborde; J L Slightom; A E Berger; M J Bienkowski; F F Sun; R N McEwan
Journal:  Nature       Date:  1990-04-12       Impact factor: 49.962

6.  Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist.

Authors:  S P Eisenberg; R J Evans; W P Arend; E Verderber; M T Brewer; C H Hannum; R C Thompson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

7.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock.

Authors:  K Ohlsson; P Björk; M Bergenfeldt; R Hageman; R C Thompson
Journal:  Nature       Date:  1990-12-06       Impact factor: 49.962

8.  Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55.

Authors:  H Tilg; E Trehu; M B Atkins; C A Dinarello; J W Mier
Journal:  Blood       Date:  1994-01-01       Impact factor: 22.113

9.  Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor.

Authors:  E V Granowitz; B D Clark; J Mancilla; C A Dinarello
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

10.  In vivo changes in plasma acute phase protein levels in the rat induced by slow release of IL-1, IL-6 and TNF.

Authors:  E J Lewis; A D Sedgwick; T H Hanahoe
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

View more
  3 in total

1.  Effect of montelukast, a cysteinyl receptor antagonist, on myofibroblasts in interstitial lung disease.

Authors:  Elizabeth Fireman; Yehuda Schwartz; Abraham Mann; Joel Greif
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

2.  Bronchoalveolar-Lavage-Derived Fibroblast Cell Lines Provide Tools for Investigating Various Interstitial Lung Diseases.

Authors:  Siri Lehtonen; Riitta Kaarteenaho
Journal:  Cells       Date:  2022-07-18       Impact factor: 7.666

3.  Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Christopher J Ryerson; Jeffrey L Myers; Michael Kreuter; Martina Vasakova; Elena Bargagli; Jonathan H Chung; Bridget F Collins; Elisabeth Bendstrup; Hassan A Chami; Abigail T Chua; Tamera J Corte; Jean-Charles Dalphin; Sonye K Danoff; Javier Diaz-Mendoza; Abhijit Duggal; Ryoko Egashira; Thomas Ewing; Mridu Gulati; Yoshikazu Inoue; Alex R Jenkins; Kerri A Johannson; Takeshi Johkoh; Maximiliano Tamae-Kakazu; Masanori Kitaichi; Shandra L Knight; Dirk Koschel; David J Lederer; Yolanda Mageto; Lisa A Maier; Carlos Matiz; Ferran Morell; Andrew G Nicholson; Setu Patolia; Carlos A Pereira; Elisabetta A Renzoni; Margaret L Salisbury; Moises Selman; Simon L F Walsh; Wim A Wuyts; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2020-08-01       Impact factor: 30.528

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.